ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bortezomib

Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.

Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.

Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 15, 201462 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson285 open or runningphase 4since Oct 15, 2014Sep 13, 2005Feb 14, 2029phase 3 · NCT04923893
Takedaits history only250 open or runningphase 4since Nov 18, 2005Oct 28, 2002none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Apr 24, 2006Apr 19, 2006none ahead
AbbVieits history only32 open or runningphase 3since Nov 28, 2023Aug 19, 2016Dec 2027phase 3 · NCT06158841
AstraZenecaits history only10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
Clinical Service, Chinaits history only10 open or runningphase 2since Mar 29, 2011Mar 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Sep 13, 2005.

  1. Jan 27, 2011Phase 2 study in Multiple MyelomaNCT01286077 · 106 enrolled · Austria, Czech Republic, Denmark and more
  2. Nov 23, 2011Phase 3 study in Multiple MyelomaNCT01539083 · 256 enrolled · Australia, China, Korea, Republic of
  3. Feb 4, 20132 phase 3 studies in Multiple MyelomaNCT01910987, NCT01801436
  4. Jun 7, 2013Phase 2 study in Lymphoma, FollicularNCT01902862 · 7 enrolled · Germany
  5. Oct 15, 2014Phase 4 study in Multiple MyelomaNCT02268890 · 18 enrolled · Taiwan
  6. May 26, 2016Phase 3 study in Multiple MyelomaNCT02811978 · 81 enrolled · China
  7. Aug 1, 2016Phase 2 study in Multiple MyelomaNCT02874742 · 224 enrolled · United States
  8. Oct 31, 2016Phase 2 study in Multiple MyelomaNCT02951819 · 101 enrolled · United States
  9. Nov 27, 2019Phase 3 study in Multiple MyelomaNCT04181827 · 419 enrolled · United States, Australia, Belgium and more
  10. Jun 10, 2021Phase 3 study in Multiple MyelomaNCT04923893 · 743 enrolled · United States, Argentina, Australia and more
  11. Oct 8, 2021Phase 3 study in Multiple MyelomaNCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
  12. Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellNCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
  13. Oct 5, 2022Phase 3 study in Multiple MyelomaNCT05572515 · 614 enrolled · United States, Australia, Austria and more
  14. Aug 27, 2024Phase 2 study in Multiple MyelomaNCT06577025 · 43 enrolled · United States, Australia, Brazil and more

Ahead

  1. Feb 14, 2029Primary completion: phase 3 study in Multiple MyelomaNCT04923893
  2. Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaNCT06577025

TargetBeta

“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
carfilzomibruleAmgenphase 438

Studies

All 28 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06577025Multiple Myeloma · United States, Australia, Brazil and more2Active, not recruitingSep 2, 203043
NCT05572515Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingOct 13, 2025614
NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more2CompletedDec 6, 202336
NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more3Active, not recruitingAug 1, 2025587
NCT04923893Multiple Myeloma · United States, Argentina, Australia and more3Active, not recruitingFeb 14, 2029743
NCT04181827Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingMay 1, 2024419
NCT02951819Multiple Myeloma · United States2CompletedMar 8, 2018101
NCT02874742Multiple Myeloma · United States2CompletedJan 25, 2019224
NCT02811978Multiple Myeloma · China3CompletedMay 7, 201881
NCT02268890Multiple Myeloma · Taiwan4CompletedJul 201518
NCT01902862Lymphoma, Follicular · Germany2TerminatedAug 20077
NCT01801436Multiple Myeloma3CompletedApr 200814
NCT01910987Multiple Myeloma · Belgium, Finland, France and more3CompletedFeb 201680
NCT01539083Multiple Myeloma · Australia, China, Korea, Republic of3CompletedDec 30, 2015256
NCT01286077Multiple Myeloma · Austria, Czech Republic, Denmark and more2CompletedNov 2012106
NCT00985959Multiple Myeloma · Japan1CompletedJun 2010101
NCT00908232Multiple Myeloma · France, Germany, Greece and more2CompletedAug 2011163
NCT00833560Multiple Myeloma · Germany2CompletedJun 2009401
NCT00813150Multiple Myeloma · Germany3CompletedJan 201396
NCT00752518Multiple Myeloma2Completed35
NCT00718640Multiple Myeloma · Canada2TerminatedDec 200910
NCT00706953Multiple Myeloma2WithdrawnJun 20100
NCT00561743Multiple Myeloma2CompletedMay 200750
NCT00441168Multiple Myeloma · Croatia, Germany, Hungary and more2TerminatedJan 200830
NCT00431769Multiple Myeloma · Austria, Belgium, France and more2CompletedFeb 2009130
NCT00416273Multiple Myeloma · Germany3CompletedMay 2013217
NCT00416208Multiple Myeloma · Germany3CompletedMay 2013154
NCT00216697Multiple Myeloma2Completed13

How it is read

Names in the registry

  • “Bortezomib”, 42 entries
  • “bortezomib”, 18 entries
  • “VELCADE”, 6 entries
  • “VELCADE TM (bortezomib) for Injection”, 2 entries
  • “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.